Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside
Tóm tắt
Từ khóa
Tài liệu tham khảo
Gaoni, 1964, Isolation, structure and partial synthesis of an active constituent of hashish, J Am Chem Soc, 86, 1946, 10.1021/ja01062a046
Matsuda, 1990, Structure of a cannabinoid receptor and functional expression of the cloned cDNA, Nature, 346, 561, 10.1038/346561a0
Munro, 1993, Molecular characterization of a peripheral receptor for cannabinoids, Nature, 365, 61, 10.1038/365061a0
Guindon, 2008, Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain, Br J Pharmacol, 153, 319, 10.1038/sj.bjp.0707531
Ledent, 1999, Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice, Science, 283, 401, 10.1126/science.283.5400.401
Buckley, 2000, Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor, Eur J Pharmacol, 396, 141, 10.1016/S0014-2999(00)00211-9
Agarwal, 2007, Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors, Nat Neurosci, 10, 870, 10.1038/nn1916
Herkenham, 1991, Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study, J Neurosci, 11, 563, 10.1523/JNEUROSCI.11-02-00563.1991
Matsuda, 1993, Localization of cannabinoid receptor mRNA in rat brain, J Comp Neurol, 327, 535, 10.1002/cne.903270406
Hohmann, 1999, Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study, Neuroscience, 90, 923, 10.1016/S0306-4522(98)00524-7
Malan, 2001, CB2 cannabinoid receptor-mediated peripheral antinociception, Pain, 93, 239, 10.1016/S0304-3959(01)00321-9
Facci, 1995, Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide, Proc Natl Acad Sci U S A, 92, 3376, 10.1073/pnas.92.8.3376
Ross, 2001, Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception, Neuropharmacology, 40, 221, 10.1016/S0028-3908(00)00135-0
Van Sickle, 2005, Identification and functional characterization of brainstem cannabinoid CB2 receptors, Science, 310, 329, 10.1126/science.1115740
Gong, 2006, Cannabinoid CB2 receptors: immunohistochemical localization in rat brain, Brain Res, 1071, 10, 10.1016/j.brainres.2005.11.035
Ashton, 2006, Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study, Neurosci Lett, 396, 113, 10.1016/j.neulet.2005.11.038
Beltramo, 2006, CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms, Eur J Neurosci, 23, 1530, 10.1111/j.1460-9568.2006.04684.x
Wotherspoon, 2005, Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons, Neuroscience, 135, 235, 10.1016/j.neuroscience.2005.06.009
Devane, 1992, Isolation and structure of a brain constituent that binds to the cannabinoid receptor, Science, 258, 1946, 10.1126/science.1470919
Mechoulam, 1995, Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors, Biochem Pharmacol, 50, 83, 10.1016/0006-2952(95)00109-D
Sugiura, 1995, 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain, Biochem Biophys Res Commun, 215, 89, 10.1006/bbrc.1995.2437
Hanus, 2001, 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor, Proc Natl Acad Sci U S A, 98, 3662, 10.1073/pnas.061029898
Porter, 2002, Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor, J Pharmacol Exp Ther, 301, 1020, 10.1124/jpet.301.3.1020
Huang, 2002, An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors, Proc Natl Acad Sci U S A, 99, 8400, 10.1073/pnas.122196999
Fezza, 2008, Fatty acid amide hydrolase: a gate-keeper of the endocannabinoid system, Subcell Biochem, 49, 101, 10.1007/978-1-4020-8831-5_4
Lo Verme, 2005, The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide, Mol Pharmacol, 67, 15, 10.1124/mol.104.006353
Re, 2007, Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals, Vet J, 173, 21, 10.1016/j.tvjl.2005.10.003
Bisogno, 2002, Fatty acid amide hydrolase, an enzyme with many bioactive substrates, Curr Pharm Des, 8, 533, 10.2174/1381612023395655
Cravatt, 2001, Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase, Proc Natl Acad Sci U S A, 98, 9371, 10.1073/pnas.161191698
Lichtman, 2004, Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia, Pain, 109, 319, 10.1016/j.pain.2004.01.022
Ross, 2001, Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens, Br J Pharmacol, 132, 631, 10.1038/sj.bjp.0703850
Bouaboula, 2005, Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation, Eur J Pharmacol, 517, 174, 10.1016/j.ejphar.2005.05.032
Hohmann, 2005, An endocannabinoid mechanism for stress-induced analgesia, Nature, 435, 1108, 10.1038/nature03658
Dinh, 2002, Brain monoglyceride lipase participating in endocannabinoid inactivation, Proc Natl Acad Sci U S A, 99, 10819, 10.1073/pnas.152334899
Walker, 2005, Cannabinoid mechanisms of pain suppression, Handb Exp Pharmacol, 509, 10.1007/3-540-26573-2_17
Bennett, 1988, A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man, Pain, 33, 87, 10.1016/0304-3959(88)90209-6
Lim, 2003, Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats, Pain, 105, 275, 10.1016/S0304-3959(03)00242-2
Wang, 2007, Central glucocorticoid receptors regulate the upregulation of spinal cannabinoid-1 receptors after peripheral nerve injury in rats, Pain, 131, 96, 10.1016/j.pain.2006.12.019
Costa, 2007, The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain, Eur J Pharmacol, 556, 75, 10.1016/j.ejphar.2006.11.006
Comelli, 2008, Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: mechanisms involved, Phytother Res, 22, 1017, 10.1002/ptr.2401
Herzberg, 1997, The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain, Neurosci Lett, 221, 157, 10.1016/S0304-3940(96)13308-5
Costa, 2005, Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve, Pain, 116, 52, 10.1016/j.pain.2005.03.043
Ibrahim, 2003, Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS, Proc Natl Acad Sci U S A, 100, 10529, 10.1073/pnas.1834309100
Sain, 2009, Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(−/−) and not CB2(−/−) mice in models of acute and persistent pain, Neuropharmacology, 57, 235, 10.1016/j.neuropharm.2009.06.004
Strangman, 1999, Cannabinoid WIN 55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses, J Neurophysiol, 82, 472, 10.1152/jn.1999.82.1.472
Liu, 2006, Effects of a cannabinoid agonist on spinal nociceptive neurons in a rodent model of neuropathic pain, J Neurophysiol, 96, 2984, 10.1152/jn.00498.2006
Costa, 2004, Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain, Br J Pharmacol, 141, 4, 10.1038/sj.bjp.0705587
Zhang, 2003, Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models, Eur J Neurosci, 17, 2750, 10.1046/j.1460-9568.2003.02704.x
Hu, 2009, Depression-like behaviour in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833, Pain, 10.1016/j.pain.2009.02.018
Costa, 2006, AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain, Br J Pharmacol, 148, 1022, 10.1038/sj.bjp.0706798
La Rana, 2006, Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide], J Pharmacol Exp Ther, 317, 1365, 10.1124/jpet.105.100792
La Rana, 2008, AM404, an anandamide transport inhibitor, reduces plasma extravasation in a model of neuropathic pain in rat: role for cannabinoid receptors, Neuropharmacology, 54, 521, 10.1016/j.neuropharm.2007.10.021
Russo, 2007, The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3′-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice, J Pharmacol Exp Ther, 322, 236, 10.1124/jpet.107.119941
Petrosino, 2007, Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats, Neuropharmacology, 52, 415, 10.1016/j.neuropharm.2006.08.011
Palazzo, 2006, Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system, Eur J Neurosci, 24, 2011, 10.1111/j.1460-9568.2006.05086.x
Rodella, 2005, AM404, an inhibitor of anandamide reuptake decreases Fos-immunoreactivity in the spinal cord of neuropathic rats after non-noxious stimulation, Eur J Pharmacol, 508, 139, 10.1016/j.ejphar.2004.12.031
Kinsey, 2009, Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain, J Pharmacol Exp Ther, 10.1124/jpet.109.155465
Costa, 2008, The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors, Pain, 10.1016/j.pain.2008.06.003
Seltzer, 1990, A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury, Pain, 43, 205, 10.1016/0304-3959(90)91074-S
Jayamanne, 2006, Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models, Br J Pharmacol, 147, 281, 10.1038/sj.bjp.0706510
Racz, 2008, Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain, J Neurosci, 28, 12125, 10.1523/JNEUROSCI.3400-08.2008
Wallace, 2007, The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy, Br J Pharmacol, 151, 1117, 10.1038/sj.bjp.0707326
Helyes, 2003, Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat, Life Sci, 73, 2345, 10.1016/S0024-3205(03)00651-9
Guindon, 2006, Antihyperalgesic effects of local injections of anandamide, ibuprofen, rofecoxib and their combinations in a model of neuropathic pain, Neuropharmacology, 50, 814, 10.1016/j.neuropharm.2005.12.002
Desroches, 2008, Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model, Br J Pharmacol, 155, 913, 10.1038/bjp.2008.322
Fox, 2001, The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain, Pain, 92, 91, 10.1016/S0304-3959(00)00474-7
Dyson, 2005, Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat, Pain, 116, 129, 10.1016/j.pain.2005.03.037
Yamamoto, 2008, Involvement of central cannabinoid CB2 receptor in reducing mechanical allodynia in a mouse model of neuropathic pain, Eur J Pharmacol, 583, 56, 10.1016/j.ejphar.2008.01.010
Racz, 2008, Interferon-gamma is a critical modulator of CB(2) cannabinoid receptor signaling during neuropathic pain, J Neurosci, 28, 12136, 10.1523/JNEUROSCI.3402-08.2008
Staton, 2008, The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain, Pain, 139, 225, 10.1016/j.pain.2008.04.006
Mitchell, 2007, Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models, Clin Exp Pharmacol Physiol, 34, 1186, 10.1111/j.1440-1681.2007.04692.x
Lambert, 1999, The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic?, Curr Med Chem, 6, 757, 10.2174/0929867306666220401153732
Vuong, 2008, Actions of N-arachidonyl-glycine in a rat neuropathic pain model, Neuropharmacology, 54, 189, 10.1016/j.neuropharm.2007.05.004
Dani, 2007, The local antinociceptive effects of paracetamol in neuropathic pain are mediated by cannabinoid receptors, Eur J Pharmacol, 573, 214, 10.1016/j.ejphar.2007.07.012
Kim, 1992, An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat, Pain, 50, 355, 10.1016/0304-3959(92)90041-9
De Vry, 2004, 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfo nate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects, J Pharmacol Exp Ther, 310, 620, 10.1124/jpet.103.062836
Bridges, 2001, The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain, Br J Pharmacol, 133, 586, 10.1038/sj.bjp.0704110
LaBuda, 2005, Pharmacological evaluation of the selective spinal nerve ligation model of neuropathic pain in the rat, J Neurosci Methods, 144, 175, 10.1016/j.jneumeth.2004.11.008
Leichsenring, 2009, Analgesic and antiinflammatory effects of cannabinoid receptor agonists in a rat model of neuropathic pain, Naunyn Schmiedebergs Arch Pharmacol, 379, 627, 10.1007/s00210-008-0386-4
Chapman, 2001, Functional changes in the inhibitory effect of spinal cannabinoid (CB) receptor activation in nerve injured rats, Neuropharmacology, 41, 870, 10.1016/S0028-3908(01)00125-3
Mitrirattanakul, 2006, Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain, Pain, 126, 102, 10.1016/j.pain.2006.06.016
Kawasaki, 2006, Different effects of opioid and cannabinoid receptor agonists on C-fiber-induced extracellular signal-regulated kinase activation in dorsal horn neurons in normal and spinal nerve-ligated rats, J Pharmacol Exp Ther, 316, 601, 10.1124/jpet.105.093583
Naguib, 2008, MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models, Br J Pharmacol, 155, 1104, 10.1038/bjp.2008.340
Elmes, 2004, Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naive rats and in rat models of inflammatory and neuropathic pain, Eur J Neurosci, 20, 2311, 10.1111/j.1460-9568.2004.03690.x
Jhaveri, 2008, Evidence for a novel functional role of cannabinoid CB(2) receptors in the thalamus of neuropathic rats, Eur J Neurosci, 27, 1722, 10.1111/j.1460-9568.2008.06162.x
McGaraughty, 2009, A CB(2) receptor agonist, A-836339, modulates wide dynamic range neuronal activity in neuropathic rats: contributions of spinal and peripheral CB(2) receptors, Neuroscience, 158, 1652, 10.1016/j.neuroscience.2008.11.015
Rahn, 2008, Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats, J Pharmacol Exp Ther, 327, 584, 10.1124/jpet.108.141994
Sit, 2007, Novel inhibitors of fatty acid amide hydrolase, Bioorg Med Chem Lett, 17, 3287, 10.1016/j.bmcl.2007.04.009
Chang, 2006, Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms, Br J Pharmacol, 148, 102, 10.1038/sj.bjp.0706699
Jhaveri, 2006, Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain, J Neurosci, 26, 13318, 10.1523/JNEUROSCI.3326-06.2006
Vos, 1991, Behavioral changes following ligation of the infraorbital nerve in rats: an animal model of trigeminal neuropathic pain, 147
Liang, 2007, The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain, Neuropharmacology, 53, 169, 10.1016/j.neuropharm.2007.04.019
Liang, 2004, Cannabinoid-induced presynaptic inhibition at the primary afferent trigeminal synapse of juvenile rat brainstem slices, J Physiol, 555, 85, 10.1113/jphysiol.2003.056986
Romero-Sandoval, 2008, Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury, Anesthesiology, 108, 722, 10.1097/ALN.0b013e318167af74
Tanga, 2005, The CNS role of Toll-like receptor 4 in innate neuroimmunity and painful neuropathy, Proc Natl Acad Sci U S A, 102, 5856, 10.1073/pnas.0501634102
Walczak, 2005, Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain, Neuroscience, 132, 1093, 10.1016/j.neuroscience.2005.02.010
Walczak, 2006, Characterization of chronic constriction of the saphenous nerve, a model of neuropathic pain in mice showing rapid molecular and electrophysiological changes, J Neurosci Res, 83, 1310, 10.1002/jnr.20821
Decosterd, 2000, Spared nerve injury: an animal model of persistent peripheral neuropathic pain, Pain, 87, 149, 10.1016/S0304-3959(00)00276-1
Decosterd, 2004, Differential analgesic sensitivity of two distinct neuropathic pain models, Anesth Analg, 99, 457, 10.1213/01.ANE.0000131967.69309.4F
Bruce, 2002, Chronic pain after clip-compression injury of the rat spinal cord, Exp Neurol, 178, 33, 10.1006/exnr.2002.8026
Hama, 2007, Antinociceptive effect of cannabinoid agonist WIN 55,212-2 in rats with a spinal cord injury, Exp Neurol, 204, 454, 10.1016/j.expneurol.2006.09.002
Hama, 2009, Sustained antinociceptive effect of cannabinoid receptor agonist WIN 55,212-2 over time in rat model of neuropathic spinal cord injury pain, J Rehabil Res Dev, 46, 135, 10.1682/JRRD.2008.04.0049
Hofmann, 2003, Pharmacological sensitivity and gene expression analysis of the tibial nerve injury model of neuropathic pain, Eur J Pharmacol, 470, 17, 10.1016/S0014-2999(03)01753-9
Siegling, 2001, Cannabinoid CB(1) receptor upregulation in a rat model of chronic neuropathic pain, Eur J Pharmacol, 415, R5, 10.1016/S0014-2999(01)00798-1
Bujalska, 2008, Effect of cannabinoid receptor agonists on streptozotocin-induced hyperalgesia in diabetic neuropathy, Pharmacology, 82, 193, 10.1159/000156485
Zhang, 2007, Expression of cannabinoid CB1 receptors in models of diabetic neuropathy, J Pharmacol Exp Ther, 323, 508, 10.1124/jpet.107.128272
Matias, 2006, Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration, Prostaglandins Leukot Essent Fatty Acids, 75, 413, 10.1016/j.plefa.2006.08.002
Engeli, 2005, Activation of the peripheral endocannabinoid system in human obesity, Diabetes, 54, 2838, 10.2337/diabetes.54.10.2838
Murdolo, 2007, Insulin differentially modulates the peripheral endocannabinoid system in human subcutaneous abdominal adipose tissue from lean and obese individuals, J Endocrinol Invest, 30, RC17, 10.1007/BF03347440
Scheen, 2009, The endocannabinoid system: a promising target for the management of type 2 diabetes, Curr Protein Pept Sci, 10, 56, 10.2174/138920309787315149
Watanabe, 2009, Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways, J Biol Chem, 284, 1803, 10.1074/jbc.M807120200
Dagon, 2007, The synthetic cannabinoid HU-210 attenuates neural damage in diabetic mice and hyperglycemic pheochromocytoma PC12 cells, Neurobiol Dis, 27, 174, 10.1016/j.nbd.2007.04.017
Williams, 2008, Decreased basal endogenous opioid levels in diabetic rodents: effects on morphine and delta-9-tetrahydrocannabinoid-induced antinociception, Eur J Pharmacol, 584, 78, 10.1016/j.ejphar.2007.12.035
Vera, 2007, WIN 55,212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat, Life Sci, 81, 468, 10.1016/j.lfs.2007.06.012
Ray, 2009, Delta 9-tetrahydrocannabinol suppresses vomiting behavior and Fos expression in both acute and delayed phases of cisplatin-induced emesis in the least shrew, Behav Brain Res, 196, 30, 10.1016/j.bbr.2008.07.028
Polomano, 2001, A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel, Pain, 94, 293, 10.1016/S0304-3959(01)00363-3
Pascual, 2005, A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats, Pain, 118, 23, 10.1016/j.pain.2005.07.008
Flatters, 2004, Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy, Pain, 109, 150, 10.1016/j.pain.2004.01.029
Weng, 2003, Changes in sensory processing in the spinal dorsal horn accompany vincristine-induced hyperalgesia and allodynia, Pain, 103, 131, 10.1016/S0304-3959(02)00445-1
Rahn, 2007, Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats, Br J Pharmacol, 152, 765, 10.1038/sj.bjp.0707333
Wallace, 2007, Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain, Brain, 130, 2688, 10.1093/brain/awm195
Wallace, 2007, Pharmacological, behavioural and mechanistic analysis of HIV-1 gp120 induced painful neuropathy, Pain, 133, 47, 10.1016/j.pain.2007.02.015
Wallace, 2003, Focal lysolecithin-induced demyelination of peripheral afferents results in neuropathic pain behavior that is attenuated by cannabinoids, J Neurosci, 23, 3221, 10.1523/JNEUROSCI.23-08-03221.2003
Lynch, 2008, Analysis of nociception, sex and peripheral nerve innervation in the TMEV animal model of multiple sclerosis, Pain, 136, 293, 10.1016/j.pain.2007.07.007
Buchanan, 2003, Gender analyses of nursing home residents with multiple sclerosis, J Gend Specif Med, 6, 35
Olechowski, 2009, Neuropathic pain behaviours in a chronic-relapsing model of experimental autoimmune encephalomyelitis (EAE), Pain, 141, 156, 10.1016/j.pain.2008.11.002
Loria, 2008, Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide, Eur J Neurosci, 28, 633, 10.1111/j.1460-9568.2008.06377.x
LoVerme, 2006, Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha, J Pharmacol Exp Ther, 319, 1051, 10.1124/jpet.106.111385
Hasnie, 2007, Further characterization of a rat model of varicella zoster virus-associated pain: Relationship between mechanical hypersensitivity and anxiety-related behavior, and the influence of analgesic drugs, Neuroscience, 144, 1495, 10.1016/j.neuroscience.2006.11.029
Beaulieu, 2007, Reassessment of the role of cannabinoids in the management of pain, Curr Opin Anaesthesiol, 20, 473, 10.1097/ACO.0b013e3282efd175
Nurmikko, 2007, Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial, Pain, 133, 210, 10.1016/j.pain.2007.08.028
Svendsen, 2004, Does the cannabinoid dronabinol reduce central pain in multiple sclerosis?, BMJ, 329, 253, 10.1136/bmj.38149.566979.AE
Abrams, 2007, Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial, Neurology, 68, 515, 10.1212/01.wnl.0000253187.66183.9c
Abrams, 2003, Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial, Ann Intern Med, 139, 258, 10.7326/0003-4819-139-4-200308190-00008
Ellis, 2009, Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial, Neuropsychopharmacology, 34, 672, 10.1038/npp.2008.120
Woolridge, 2005, Cannabis use in HIV for pain and other medical symptoms, J Pain Symptom Manage, 29, 358, 10.1016/j.jpainsymman.2004.07.011
Beal, 1995, Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS, J Pain Symptom Manage, 10, 89, 10.1016/0885-3924(94)00117-4
Vincent, 1983, Review of cannabinoids and their antiemetic effectiveness, Drugs, 25, 52, 10.2165/00003495-198300251-00006
Tramer, 2001, Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review, BMJ, 323, 16, 10.1136/bmj.323.7303.16
Malfitano, 2008, Cannabinoids in the management of spasticity associated with multiple sclerosis, Neuropsychiatr Dis Treat, 4, 847
Zajicek, 2003, Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial, Lancet, 362, 1517, 10.1016/S0140-6736(03)14738-1
Zajicek, 2005, Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up, J Neurol Neurosurg Psychiatry, 76, 1664, 10.1136/jnnp.2005.070136
Rog, 2005, Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis, Neurology, 65, 812, 10.1212/01.wnl.0000176753.45410.8b
Rog, 2007, Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial, Clin Ther, 29, 2068, 10.1016/j.clinthera.2007.09.013
Iskedjian, 2007, Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain, Curr Med Res Opin, 23, 17, 10.1185/030079906X158066
Yiangou, 2006, COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord, BMC Neurol, 6, 12, 10.1186/1471-2377-6-12
Berman, 2004, Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial, Pain, 112, 299, 10.1016/j.pain.2004.09.013
Anand, 2008, Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons, Pain, 138, 667, 10.1016/j.pain.2008.06.007
Karst, 2003, Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial, JAMA, 290, 1757, 10.1001/jama.290.13.1757
Salim, 2005, Pain measurements and side effect profile of the novel cannabinoid ajulemic acid, Neuropharmacology, 48, 1164, 10.1016/j.neuropharm.2005.02.010
Liu, 2003, Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid, Mol Pharmacol, 63, 983, 10.1124/mol.63.5.983
Wilsey, 2008, A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain, J Pain, 9, 506, 10.1016/j.jpain.2007.12.010
Notcutt, 2004, Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ‘N of 1’ studies, Anaesthesia, 59, 440, 10.1111/j.1365-2044.2004.03674.x
Walker, 2007, Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing, J Clin Sleep Med, 3, 455, 10.5664/jcsm.26908
Dimsdale, 2007, The effect of opioids on sleep architecture, J Clin Sleep Med, 3, 33
Wade, 2003, A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms, Clin Rehabil, 17, 21, 10.1191/0269215503cr581oa
Wissel, 2006, Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial, J Neurol, 253, 1337, 10.1007/s00415-006-0218-8
Berlach, 2006, Experience with the synthetic cannabinoid nabilone in chronic noncancer pain, Pain Med, 7, 25, 10.1111/j.1526-4637.2006.00085.x
Maurer, 1990, Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial, Eur Arch Psychiatry Clin Neurosci, 240, 1, 10.1007/BF02190083
Hagenbach, 2007, The treatment of spasticity with Delta9-tetrahydrocannabinol in persons with spinal cord injury, Spinal Cord, 45, 551, 10.1038/sj.sc.3101982
Attal, 2004, Are oral cannabinoids safe and effective in refractory neuropathic pain?, Eur J Pain, 8, 173, 10.1016/S1090-3801(03)00084-3
Clermont-Gnamien, 2002, The therapeutic use of D9-tetrahydrocannabinol (dronabinol) in refractory neuropathic pain, Presse Med, 31, 1840
Frank, 2008, Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study, Bmj, 336, 199, 10.1136/bmj.39429.619653.80
Pinsger, 2006, Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain—a randomized controlled trial, Wien Klin Wochenschr, 118, 327, 10.1007/s00508-006-0611-4
Narang, 2008, Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy, J Pain, 9, 254, 10.1016/j.jpain.2007.10.018
Toth, 2008, A prospective identification of neuropathic pain in specific chronic polyneuropathy syndromes and response to pharmacological therapy, Pain, 138, 657, 10.1016/j.pain.2008.04.023
Wang, 2008, Adverse effects of medical cannabinoids: a systematic review, CMAJ, 178, 1669, 10.1503/cmaj.071178
De Vry, 2004, Pharmacological characterization of the chronic constriction injury model of neuropathic pain, Eur J Pharmacol, 491, 137, 10.1016/j.ejphar.2004.03.051
Pedersen, 2006, Pharmacological characterisation of place escape/avoidance behaviour in the rat chronic constriction injury model of neuropathic pain, Psychopharmacology (Berl), 185, 208, 10.1007/s00213-005-0281-3
Hama, 2004, Antihyperalgesic effect of the cannabinoid agonist WIN55,212-2 is mediated through an interaction with spinal metabotropic glutamate-5 receptors in rats, Neurosci Lett, 358, 21, 10.1016/j.neulet.2003.12.111
Yao, 2008, In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models, Br J Pharmacol, 153, 390, 10.1038/sj.bjp.0707568
Mitchell, 2005, Effect of the cannabinoid ajulemic acid on rat models of neuropathic and inflammatory pain, Neurosci Lett, 382, 231, 10.1016/j.neulet.2005.03.019
Guindon, 2007, Pre-emptive antinociceptive effects of a synthetic cannabinoid in a model of neuropathic pain, Eur J Pharmacol, 568, 173, 10.1016/j.ejphar.2007.04.060
Valenzano, 2005, Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy, Neuropharmacology, 48, 658, 10.1016/j.neuropharm.2004.12.008
Whiteside, 2005, A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833, Eur J Pharmacol, 528, 65, 10.1016/j.ejphar.2005.10.043
Scott, 2004, Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat, Pain, 109, 124, 10.1016/j.pain.2004.01.020
Worm, 2008, Sulfamoyl benzamides as novel CB2 cannabinoid receptor ligands, Bioorg Med Chem Lett, 18, 2830, 10.1016/j.bmcl.2008.04.006
Diaz, 2008, Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain, J Med Chem, 51, 4932, 10.1021/jm8002203
Dogrul, 2004, Cannabinoids blocks tactile allodynia in diabetic mice without attenuation of its antinociceptive effect, Neurosci Lett, 368, 82, 10.1016/j.neulet.2004.06.060